Atlas Genetics is creating a new category of in vitro diagnostics focused on decentralized, near-patient and Point-of-Care (POC) testing for everyone. With routine testing rapidly moving from the “hub” to the “spokes,” Atlas’s io® platform is poised to benefit from this growing trend in decentralized testing. The company’s proprietary technology platform positions Atlas in the vanguard of the rapidly evolving and increasingly patient-directed landscape of consumer diagnostics, where convenience, rapid “test and treat,” and portability of platform are becoming critical to success. Atlas aims to meet patients where they are and improve patient outcomes by arming healthcare professionals with a simple-to-use, rapid and cost-effective solution for on-demand diagnosis of infectious diseases. Rapid turnaround times, high accuracy and low cost are hallmarks of the company’s broad platform for a broad range of infectious diseases. The io® platform offers a sample-to-answer time of 30 minutes, or less, making it possible to carry out infectious disease tests in primary care clinics and physicians’ offices anywhere.
Jeff Luber I Chief Executive Officer
Jeff has served as CEO of multiple life sciences companies in emerging healthcare markets with both public and private venture-backed companies. Prior to Atlas Genetics, Jeff served as President, Chief Executive Officer and Director of Good Start Genetics, a commercial stage provider of advanced genetic testing in reproductive health, with operations in all fifty states in the US. Under Mr. Luber’s leadership, the Company grew testing volumes by double digits, established transformative industry partnerships, and led the Company’s successful sale to Invitae Corp. (NYSE: NVTA) in August 2017. Prior to Good Start, Mr. Luber co-founded SynapDx, Corp., a venture-backed developer of blood-based testing solutions for the early detection of autism. From 2002 to 2009 Mr. Luber held numerous leadership roles with EXACT Sciences Corp., ultimately serving as its President, CEO, and Director where he led the company’s early commercial roll-out and won medical society endorsements for the company’s technologies, providing a strong platform for the company’s rapid growth and a transformative, high value partnership with Genzyme Corp. in 2009. Luber has served on numerous boards of directors of both public and private companies and earned his Juris Doctor and MBA from Suffolk University.
Marc Jones I Chief Operating Officer and Chief Financial Officer
Marc is a proven financial and operations executive who brings extensive expertise in leading financial, operational and business strategy aspects and capital formation for both large and small, public and private healthcare and technology organizations. Prior to joining Atlas Genetics, Marc was the COO & CFO of Good Start Genetics where he raised multiple successful rounds of capital, helped lead the impressive turnaround of the company to record business growth and was instrumental in its ultimate sale to publicly traded Invitae. Prior to Good Start Marc was CFO of T2 Biosystems, where he led the company's preparation for and completion of an IPO and raised nearly $100M ($70M equity + $30M in debt); he built the finance team and implemented the necessary infrastructure and processes required of a public company, and he helped drive the commercialization of the company's first FDA approved IVD product. Previously, Marc was CFO of Crashlytics where he oversaw the company's acquisition by Twitter (the largest acquisition completed by Twitter at that time). Before Crashlytics, Marc was CFO of Ivenix where he led all finance, admin and operations functions, including raising over $8M in capital. Before that, Marc served as CFO of CHiL Semiconductor, where he oversaw growth from pre-revenue to a $20M run-rate, raised $30M in venture financing, and the ultimate acquisition of the company. Earlier in his career Marc held a number of other corporate finance positions ranging from Fortune 50 companies to high-growth startups.
Ben Arlett I Chief Technology Officer
Ben joined Atlas Genetics as Technical Director in 2008. With a background in mechanical engineering he has spent his career working in innovation and new product development. His experience includes working in products from drug delivery devices to in vitro diagnostics. Ben spent four years in the US managing an engineering team in Boston as part of a new venture.
Atlas Genetics has raised approximately £63m to date from a strong investor base. The last financing raised was £28m ($35m) Series D (2016) raised from a syndicate including all Series C investors, Novartis Venture Funds, Johnson & Johnson Development Corporation, LSP (Life Science Partners), BB Biotech Ventures, Consort Medical plc, Technology Venture Partners, RMI Partners and private investors, plus Chinese biotechnology company, Wondfo Biotech.
Atlas Genetics has been awarded grant funding from the South West Regional Development Agency (SWRDA), The Wellcome Trust, the United States Institutes of Health, and a £1.6m project from The Technology Strategy Board, in partnership with Public Health England and £2m from Innovate UK as part of the Small Business Research Initiative.
Atlas Genetics is engaged in a number of collaborative projects with major diagnostic and pharmaceutical companies, and various public bodies. We aim to utilise Atlas Genetics’ technology in specific applications outside of the Company’s core product area of STIs to expand the utility of the io® platform.